Biotech firm Curis Q2 revenue rises to $2.7 mln
Overview
Curis Q2 revenue rises to $2.7 mln, beating analyst expectations
Net loss for Q2 narrows to $8.6 mln, exceeding analyst estimates
Adjusted EPS for Q2 beats expectations, reflecting improved financial performance
Outlook
Curis expects to begin enrollment for CLL study later this year
Company plans head-to-head trial against gilteritinib in AML
Curis anticipates data from AML triplet study in December
Company's cash runway extended into Q1 2026
Result Drivers
CLINICAL TRIAL PROGRESS - Curis cites ongoing enrollment in TakeAim Lymphoma study
EXPENSE REDUCTION - Lower research and development costs contributed to improved financial results
REVENUE INCREASE - Slight rise in royalty revenues from Genentech/Roche sales of Erivedge
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $2.75 mln | $2.64 mln (5 Analysts) |
Q2 Net Income | Beat | -$8.59 mln | -$14.30 mln (5 Analysts) |
Q2 Basic EPS | Beat | -$0.68 | -$0.89 (4 Analysts) |
Q2 Income From Operations | Beat | -$8.25 mln | -$14.20 mln (5 Analysts) |
Press Release: ID:nPn7pxhswa
